Judy George is a Deputy Managing Editor at ABC Network News. She specializes in medicine and healthcare, covering a range of topics including aging and longevity, mental health care, and alternative medicine, with a keen focus on health news and consumer health. Judy's work has been featured in prominent outlets such as Knowledia, Joe Miller for US Senate, MSN, and MedPage Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Judy George's coverage mainly focuses on healthcare, pharmaceuticals, and scientific research. She frequently cites data and reports on government announcements related to health topics. Therefore, she is likely to be responsive to pitches that offer access to new or exclusive data in the healthcare and pharmaceutical sector. Additionally, Judy may be interested in expert analysis or commentary on recent government announcements concerning health-related issues.
Given her extensive coverage of neurological conditions such as dementia and chronic pain, sources with expertise in these areas are likely to appeal to her. If you have insights into innovative treatments or emerging trends within the healthcare industry, particularly those related to neurology or chronic pain management, Judy would likely find them valuable for her reporting.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— IBD risk was higher with rituximab versus other MS drugs, but cumulative incidence was low
The anti-CD20 agent rituximab was associated with a higher risk of inflammatory bowel disease (IBD) in people with relapsing-remitting multiple
44 days after zola-cel treatment, MS patient dies of septic pneumonia
By: Judy George
Twice daily oral doses of 100 mg of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib reduced relapses more than teriflunomide (Aubagio) in
The investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy zolacabtagene autoleucel (zola-cel) showed the potential to treat
By: Judy George
Multiple sclerosis (MS) patients exposed to a GLP-1 receptor agonist had lower rates of relapse activity and steroid use, reduced incidence of optic
By: Judy George
News and commentary from the world of neurology and neuroscience
Potential treatment for relapsing and progressive MS under FDA priority review
The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested.
— Progressive supranuclear palsy associated with proximity to industrial facilities in U.K. study
